戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 (e.g. CD30 and CD52), and immunotoxins (e.g. denileukin diftitox).
2 g cells are depleted after multiple doses of denileukin diftitox.
3 NM) stage, histologic grade, and response to denileukin diftitox.
4 e susceptibility of T-cell leukemia cells to denileukin diftitox.
5                                 Injection of denileukin diftitox 1 day before vaccination enhanced an
6 ses of bexarotene (75 mg/day-300 mg/day) and denileukin diftitox (18 mcg/kg per day x 3 days every 21
7                                              Denileukin diftitox, a genetically engineered fusion pro
8  of two dose levels (9 or 18 microg/kg/d) of denileukin diftitox administered 5 consecutive days ever
9                                              Denileukin diftitox, also known as DAB(389)IL-2 or Ontak
10  results demonstrate that the combination of denileukin diftitox and bexarotene is well tolerated and
11  toxin conjugate DAB(389)IL-2 (also known as denileukin diftitox and ONTAK) is capable of enhancing t
12                    Our results indicate that denileukin diftitox and other suppressor cell-depleting
13 tients receiving standard 5-day infusions of denileukin diftitox at 18 microg/kg/day.
14                                              Denileukin diftitox (DAB(389)IL-2), a fusion protein of
15                                              Denileukin diftitox (DAB-IL-2, Ontak) is a diphtheria-to
16 he efficacy, safety, and pharmacokinetics of denileukin diftitox (DAB389IL-2, Ontak [Ligand Pharmaceu
17                                              Denileukin diftitox (DD), a diphtheria toxin fragment IL
18                                              Denileukin diftitox (DD), a fusion protein comprising IL
19                                              Denileukin diftitox (DD)-cxdl is a fusion protein compri
20 estigate efficacy and safety of two doses of denileukin diftitox (DD; DAB(389)-interleukin-2 [IL-2]),
21 lus etanercept, mycophenolate mofetil (MMF), denileukin diftitox (denileukin), or pentostatin.
22 ted that a CD25(high) targeting immunotoxin (denileukin diftitox) depleted FoxP3(+) Treg cells, decre
23                                     However, denileukin diftitox (DT)-mediated Treg depletion improve
24 to evaluate the efficacy and tolerability of denileukin diftitox for relapsed or refractory B-cell NH
25 sure enhanced susceptibility of the cells to denileukin diftitox fusion toxin-targeting and -intoxica
26                   In a pilot study (n = 15), denileukin diftitox, given as a single dose or repeated
27 0% of the 71 patients with CTCL treated with denileukin diftitox had an objective response (20% parti
28  knowledge we report for the first time that denileukin diftitox has also dramatic effects regarding
29                                              Denileukin diftitox has been shown to be a useful and im
30 ected therapies, including the fusion toxin, denileukin diftitox, histone deacetylase inhibitors, and
31 depleted with the IL-2-toxin fusion protein (denileukin diftitox), HIV-1 infection is significantly i
32              We conducted a phase 1 study of denileukin diftitox in 30 patients with steroid refracto
33                 We evaluated the activity of denileukin diftitox in an acute mouse model of tuberculo
34  compartments and (2) the dose scheduling of denileukin diftitox in combination with a recombinant po
35                                Evaluation of denileukin diftitox in combination with other agents may
36                       Tregs were depleted by denileukin diftitox in humanized mice with chronic HIV-1
37 performed in vivo Treg depletion with Ontak (denileukin diftitox) in two SIVsab-infected controller m
38                       Repeated injections of denileukin diftitox into female NOD mice at 12 wk of age
39                                              Denileukin diftitox is a fusion protein combining diphth
40                                   Meanwhile, denileukin diftitox is also used as an adjuvant in other
41                                              Denileukin diftitox is tolerable and has promising activ
42      These finding should be considered when denileukin diftitox is used for the treatment of patient
43 abetes, we demonstrate that the injection of denileukin diftitox leads to a dramatic development of t
44                                 Pentostatin, denileukin diftitox, mycophenolate mofetil, extracorpore
45 une responses, (3) the lack of inhibition by denileukin diftitox of host immune responses directed ag
46 In this study, we examined (1) the effect of denileukin diftitox on the deletion of Treg cells in var
47 murine model (1) the differential effects of denileukin diftitox on Treg cells in different cellular
48                                              Denileukin diftitox (Ontak), a recombinant fusion protei
49                                              Denileukin diftitox (Ontak), a recombinant protein compo
50 totherapy, and monoclonal antibodies such as denileukin diftitox or etanercept are reviewed.
51              These in vivo studies show that denileukin diftitox potentiates standard TB treatment in
52 nd combination with the IL-2 toxin conjugate denileukin diftitox resulted in more than additive toxic
53                                              Denileukin diftitox seems to be effective in relapsed or
54 cells in the tumor grafts were depleted with denileukin diftitox, suggesting that tumor-specific T ce
55  after a single intraperitoneal injection of denileukin diftitox; the reduction was evident within 24
56  advanced CTCL and with clinical response to denileukin diftitox therapy.
57 p3(+) T cells could correct the defect after denileukin diftitox treatment.
58                                              Denileukin diftitox was administered intravenously at a
59                                              Denileukin diftitox was approved for the treatment of cu
60                 However, the clinical use of denileukin diftitox was limited by vascular leak toxicit
61 ti-interleukin-2 and serum concentrations of denileukin diftitox were also measured.
62 and (4) the importance of dose scheduling of denileukin diftitox when used in combination with a vacc
63 compartments, (2) the advantage of combining denileukin diftitox with a vaccine to enhance antigen-sp